Klaus Rose

Blind Trust

How Parents with a Sick Child Can Escape the Lies, Hypocrisy and False Promises of Researchers and the Regulatory Authorities

• Broschiertes Buch

Produktbeschreibung

An insider's look into the world of pediatric drug trials: when research outcomes can quite literally represent life or death Many parents of children with serious health problems may wonder why new medicines are initially not approved for minors and, if their condition is rare, why at the same time there is such pressure to enter any young person under 18 into drug trials. So-called 'paediatric' pharmaceutical studies have become an international multi-billion business, with many careers in academia, regulatory authorities and the pharmaceutical industry based on this work, yet much of this activity is founded on a series of flawed concepts that have led to an immeasurable waste of resources and serious, ongoing medical abuse. In this revelatory book, the former head of paediatric drug research at two major pharmaceutical companies provides a guide for parents and non-specialists interested in advancing the health of children--both individuals facing serious disease and groups of children enrolled in testing programs. Rose explains the key differences between clinically-directed and administratively-directed research, what will potentially benefit or harm children, and how laws need to change around the world so that true advances can be made.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Hammersmith Health Books
• Seitenzahl: 240
• Erscheinungstermin: 27. Januar 2022
• Englisch
• Abmessung: 138mm x 216mm x 27mm
• Gewicht: 420g
• ISBN-13: 9781781612026
• ISBN-10: 1781612021
• Artikelnr.: 61678677

Autorenporträt

Klaus Rose MD MS is a medical doctor who worked in the pharmaceutical industry for 20 years. He was an enthusiast for pharmaceutical studies in children and became global head of paediatric research first at Novartis and then Genentech/Roche before becoming an independent advisor on paediatric studies for drug approval in 2011. Through this work he came to understand that a large proportion of 'investigations' in children are not only unnecessary but ethically questionable, and that these problems are masked by a stated intention of 'helping children' that is hard to challenge.